The Schall Law Firm Invites Blueprint Medicines Corporation Investors To Join Investigation Into Potential Securities Law ViolationsAccesswire • 08/17/24
The Schall Law Firm Asks Blueprint Medicines Corporation Shareholders To Participate In Investigation Into Potential Securities Law ViolationsAccesswire • 08/16/24
The Schall Law Firm Invites Investors In Blueprint Medicines Corporation To Join Investigation Into Potential Securities Law ViolationsAccesswire • 08/15/24
The Schall Law Firm Informs Investors Of Blueprint Medicines Corporation About Ongoing Investigations Into Potential Securities Law ViolationsAccesswire • 08/15/24
The Schall Law Firm Notifies Investors Of Blueprint Medicines Corporation About Ongoing Investigations Into Potential Securities Law ViolationsAccesswire • 08/14/24
Investors Of Blueprint Medicines Corporation Are Informed By The Schall Law Firm About Ongoing Investigations Into Possible Securities Law BreachesAccesswire • 08/13/24
Levi & Korsinsky Reminds Shareholders of an Investigation into Blueprint Medicines Corporation (BPMC) Regarding Potential Securities Fraud AllegationsAccesswire • 08/12/24
Shareholders that lost money on Blueprint Medicines Corporation(BPMC) should contact Levi & Korsinsky about Securities Fraud Investigation - BPMCAccesswire • 08/11/24
Investors Of Blueprint Medicines Corporation Are Notified By The Schall Law Firm Regarding Ongoing Investigations Into Potential Securities Law ViolationsAccesswire • 08/10/24
Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 08/09/24
Investors Of Blueprint Medicines Corporation Are Alerted By The Schall Law Firm About Continuing Probes Into Possible Securities Law BreachesAccesswire • 08/09/24
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Potential Securities Law ViolationsAccesswire • 08/07/24
Blueprint Medicines Corporation Investors Are Informed By The Schall Law Firm Of Current Investigations Into Potential Securities Law ViolationsAccesswire • 08/06/24
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/01/24
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidancePRNewsWire • 08/01/24
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law BreachesAccesswire • 07/26/24
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/25/24
Blueprint Medicines Corporation Investors Are Informed By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law BreachesAccesswire • 07/19/24
The Schall Law Firm Is Currently Investigating Potential Violations Of Securities Laws For Investors Of Blueprint Medicines CorporationAccesswire • 07/18/24
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024PRNewsWire • 07/18/24
The Schall Law Firm Is Presently Probing Possible Breaches Of Securities Laws For Blueprint Medicines Corporation InvestorsAccesswire • 07/17/24
The Schall Law Firm Is At Present Conducting An Inquiry Into Possible Breaches Of Securities Laws For Blueprint Medicines Corporation InvestorsAccesswire • 07/13/24